Gastroenterology
Pipeline
5 projects
(3 in clinical development)
Life Cycle
Normix, Tixteller, Xifaxan (rifaximin)
Fully developed by Alfasigma
Indicated for Hepatic Encephalopaty, Traveler’s diarrhea, IBS
Research & Innovation
Innovation
fueled by Passion
While supporting existing assets and developing new indications to address unmet needs, our Research & Development Department is focused on three main therapeutic areas: gastroenterology, vascular disease & neuroscience disorders.
Our new strategic plan deals with next decades challenges in healthcare, leveraging opportunities in precision medicine, maximizing existing competencies in microbiome, acquiring new assets in late stage development.
We are partnering with other organizations to exploit new opportunities through big data, new technologies, and patient engagement projects.
Our main R&D therapeutic areas
Pipeline
Life Cycle
Vascular
Pipeline
1 project
Life Cycle
Vessel (Sulodexide)
Fully developed by Alfasigma
Indicated for Venous disorders (CVI, rDVT), Arterial disorders (PAOD)
Neuroscience
Pipeline
New projects under assessment
Life Cycle
Deplin (L-Methylfolate)
Indicated as Medical
Food for co-treatment
in Depressive
Disorders
Microbiome as main innovation R&D engines
Rifaximin
is one of the most effective microbiome modifier on the market
Irritable
Bowel Disease
Hepatic
Encephalopathy
Novel agents
Under exploration
Read More
Mutual growth, transparency and patient centricity are the values that guide our dialogue with the medical community.
Reporting an adverse event is important in order to safeguard the patients who are taking it and ensure a favourable benefit-risk balance for the population.
During COVID-19 emergency, we strived to solidify and maintain our relationships with stakeholders by supporting them through numerous initiatives across the world.